The P-III (APHINITY) study evaluating Perjeta + Herceptin & CT vs Herceptin & CT in 4804 patients with HER2+ early breast cancer
The results showed the continued benefit when given post-surgery IV treatment at 8.4yrs. median follow-up, treatment effect continues to be observed regardless of HR status, fewer deaths were observed (7.0% vs 8.4%), OS data remain immature & statistical significance has not yet been reached
In the overall study population/LN+ disease/ HR+/ HR- disease, reduction in risk of breast cancer recurrence or death (23%/28% with an absolute benefit of 4.9%/ 25%/18%). Patients remained disease-free (88.4% vs 85.8%) with an absolute benefit of 2.6% & the safety profile was consistent with prior studies with no new or unexpected safety signals
Ref: GlobalNewswire | Image: Roche
